Tracer library / [225Ac]Ac-DOTA-anti-CD33

[225Ac]Ac-DOTA-anti-CD33

Also written as [Ac-225]DOTA-anti-CD33

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 1

Leukemia (acute and chronic)

What it is

Compound class: DOTA-conjugated anti-CD33 monoclonal antibody (radioimmunoconjugate)
Target / mechanism: CD33 PMID 41282197
Clinical application: Radioimmunotherapy for Acute Myeloid Leukemia PMID 41282197
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	40 ± 0.45 %	>98%	DOTA-anti-CD33 Creative Biolabs	41282197 2025 Res Sq For radiolabeling of DOTA-anti-CD33 with 225Ac, an aliquot of 4 μL (approx. 1.11 MBq) of Ac-225 was added to a vial - [225Ac]DOTA-anti-CD33 was obtained with a radiochemical yield of 40 ± 0.45 % yield (n = 4 syntheses) with a radiochemical purity of more than 98%

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Creative Biolabs
Typical final purification: —

Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-anti-CD33, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41282197: 'DOTA-anti-CD33'. Stage set/updated at stage 23 from PMID 41282197: 'including [225Ac]DOTA-anti-CD33, a clinical stage-radioimmunotherapy under evaluation in AML'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review. | Stage 30 (2026-09-18): Stage was 'clinical stage'; normalised to 'Clinical research', original wording kept here.